Merck Seeks U.S. Emergency Approval For Antiviral Covid Pill A late-stage trial showed the pill, which Merck is developing with Miami-based Ridgeback Biotherapeutics, halves the chances of hospitalization or death in recently diagnosed patients at risk of severe illness.